AptarGroup
- Market cap
- 7.66B
- P/E (TTM)i
- 21.74
- P/Bi
- 2.91
- EPSi
- 5.89
- Div yieldi
- 1.57%
- 52W posi
- 42%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
- Implied fair-value range of 144.47-199.24, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -29.9% below the average-multiple fair value of 171.85.
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| AptarGroup (ATR) | 7.66B | 21.74 | 2.91 | 1.57% |
| Intuitive Surgical (ISRG) | 146.44B | 47.54 | 8.06 | 0.00% |
| Becton Dickinson & Co (BDX) | 49.07B | 54.43 | 2.01 | 2.33% |
| ResMed (RMD) | 31.78B | 21.67 | 4.83 | 1.06% |
| Medline (MDLN) | 31.10B | 67.27 | 2.69 | 0.00% |
| Alcon (ALC) | 30.45B | 48.09 | 1.41 | 0.56% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 20.0% below Morningstar's fair value estimate.
Fair value
AptarGroup Inc is assigned a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 17% discount to our quantitative fair value estimate of $144.56 per share, which is reinforced by this estimate's low uncertainty rating.
The company's profitability strengthens our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's enterprise value to free cash flow ratio of 18.4 lies in the bottom 40% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.
On a different note, the company's balance sheet is potentially concerning. Excessive leverage heightens financial risk, potentially undermining a firm's value. The firm's EBITDA/interest coverage ratio of 12.8, for example, ranks in the bottom 50% globally. This gives us pause, as it can be a warning sign of financial distress if conditions don't improve. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
By Quantitative Equity Report
Quote time 2026-10-08 08:16:30 · For reference only, not investment advice and not tailored to your situation.